Ricerc@Sapienza

To the Editor
The paper by Jones et al. in which they studied the response of a
cohort of 19 patients with adult-onset diabetes who were glutamic
acid decarboxylase autoantibodies (GADA) positive, most with very
low levels of C peptide and multiple autoantibodies, is consistent with
published results studying GLP-1 agonists in patients with established
type 1 diabetes who show little by way of a beneficial response.1,2
Importantly, they note that those with GADA, who were not on insulin

AIMS:
Patients with a type-2-diabetes (T2D) phenotype positive for glutamic acid decarboxylase antibodies (GADA) represent the majority of cases of latent autoimmune diabetes of the adult (LADA). The GLP-1 receptor agonist dulaglutide, recently introduced for treatment of T2D, has yet to be evaluated in LADA patients. Our primary objective was to evaluate the effect of dulaglutide on glycaemic control (HbA1c) in GADA-positive LADA vs GADA-negative T2D patients.
METHODS:

This exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a continuous range of baseline HbA1c values using data from three phase III randomised controlled trials.